Neuroprotection in stroke.
Stroke is the leading cause of death and disability worldwide. rt-PA is the approved drug and its use is restricted only to the first 3-4.5 hours of stroke. The review focuses on key events during early stages of ischaemic stroke and on pathogenic roles of distinctive molecules and metabolic pathways that compromise cell survival and affect infarct progression. An overview of various neuroprotective strategies is presented in this article.
Khurana
Dheeraj
D
Department of Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012.
Bal
Simerpreet
S
D001831:Body Temperature; D002986:Clinical Trials as Topic; D006801:Humans; D006943:Hyperglycemia / Q000517:prevention & control; D006973:Hypertension / Q000517:prevention & control; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control
D018696:Neuroprotective Agents